Although promising results have been reported, retatrutide is still under clinical investigation and has not yet received widespread approval for routine medical use in many countries
In SURMOUNT-5, GI side effects causing discontinuation were lower with tirzepatide (2.7%) than semaglutide (5.6%)
Miao X, Alidadipour A, Saed V, Sayyadi F, Jadidi Y, Davoudi M, Amraee F, Jadidi N, Afrisham R
Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers
Lower activity levels
Studies have even indicated that MOTS-c can reverse diet-induced obesity and insulin resistance, underscoring its significant metabolic potential